Table S2 Inhibitors of CDKs

Name	Inhibitor	Clinical stage	Delivery	Mechanism and synergistic effect	Reference
CDK1	BEY-1107, Roniciclib	Phase I/II	PO	Kinase activity, VEGFR	(132)
CDK2	Inditinib, FN-1501, Milciclib, PF-06873600, CYC-065, Seliciclib, Roniciclib	Phase I/II	IV/PO	Kinase activity, Src family	(132)
CDK3	Roniciclib	Phase I/II	PO	Kinase activity, VEGFR	(132)
CDK4	Palbociclib, Ribociclib, Abemaciclib, Trilaciclib, Lerociclib, SHR-6390, MM-D37K, PF-06873600, Birociclib, BPI-16350, FCN-437, BEBT-209, TQB-3616, Roniciclib, AMG-925	Phase I/II	IV/PO	Kinase activity, FLT3	(132)
CDK6	Palbociclib, Ribociclib, Abemaciclib, Trilaciclib, Lerociclib, SHR-6390, MM-D37K, PF-06873600, Birociclib, BPI-16350, FCN-437, BEBT-209, TQB-3616, AMG-925	Phase I/II	IV/PO	Kinase activity, FLT3	(132)
CDK7	C7001, SY-1365, Roniciclib	Phase I/II	PO/IV	Kinase activity	(132)

CDK8	BCD-115	Phase II	PO	Kinase activity	(132)
CDK9	Flavopiridol, Zotiraciclib, CYC-065, Seliciclib, AT-7519, AZD-4573, TP-1287, Voruciclib, BAY-1251152, Roniciclib, Atuveciclib	Phase I/II	IV/PO	Kinase activity, FLT3, JAK2, MAPK7, GSK3β, VEGFR	(132)
CDK12	Dinaciclib, THZ1, THZ531, E9, CDK12-IN-3, SR 4835, Procaterol	Phase I	IV	Kinase activity, IPA, DDR, MYC, SEATF, p-RNA POⅡ, RNA POLⅡ, MCL1,PARPc, DDC, PARPi	(28,132)
CDK19	BCD-115	Phase II	PO	Kinase activity	(132)

Abbreviation: PO: per os, IV: Injection of vein. DDC: DNA damage chemotherapy, RNA POL II: RNA polymerase II, IPA: Intronic polyadenylation, PARPi: PARP inhibitors, PARPc: PARP cleavage, SEATF: SE-associated transcription factors.